Zevra Therapeutics (ZVRA) Restructuring Costs (2016 - 2020)

Zevra Therapeutics (ZVRA) posted Restructuring Costs of -$2000.0 for Q4 2020, down 100.24% on a QoQ basis from $830000.0 in Q1 2020.

Zevra Therapeutics (ZVRA) Restructuring Costs (2016 - 2020) Analysis & Trends

Zevra Therapeutics' Restructuring Costs history runs 3 years deep, the most recent figure standing at -$2000.0 for Q4 2020.

Quarterly Restructuring Costs changed N/A year-over-year to -$2000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2021 was -$2000.0 (down 100.24% YoY) and the FY2020 annual result came in at $828000.0, changed N/A from the prior year.
Restructuring Costs was -$2000.0 for Q4 2020 at Zevra Therapeutics, down from $830000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $3.0 million in Q3 2016 and bottomed at -$2000.0 in Q4 2020.
A 3-year average of $1.4 million and a median of $1.2 million in 2018 frame the typical range for Restructuring Costs.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Zevra Therapeutics	239.71 Mn	39.10 Mn	34.32 Mn

Download Data